arct-032
arct-032: developed by 1 company · 1 FDA decision. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Arcturus Therapeutics Holdings Inc. (ARCT) | Phase 2 |
FDA Decisions
FDA_MeetingCompany expects meetings with the FDA and other regulatory agencies relating to the cystic fibrosis (CF) program (ARCT-032); timing is uncertain.(ARCT)
Frequently asked questions
Who is developing arct-032?
arct-032 is being developed by Arcturus Therapeutics Holdings Inc..
What is arct-032's latest FDA decision?
The most recent tracked FDA decision for arct-032 is FDA_Meeting for Company expects meetings with the FDA and other regulatory agencies relating to the cystic fibrosis (CF) program (ARCT-032); timing is uncertain..
Get deeper analysis on arct-032
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis